ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Valencia, VC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Recurrence
Cancer
Hematologic Cancer
Non-Hodgkin Lymphoma
Lymphoma
Leukemia

Multiple Myeloma trials near Valencia, VC, ESP:

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

This study is researching an investigational drug called linvoseltamab ("study drug") in participants at high risk of developing multiple my ...

Active, not recruiting
Smoldering Multiple Myeloma (SMM)
Drug: Linvoseltamab

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Valencia, Spain and 17 other locations

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Active, not recruiting
Multiple Myeloma
Drug: Isatuximab
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Valencia, Spain and 48 other locations

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood s...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Dexamethasone
Drug: Melphalan

Phase 2

PETHEMA Foundation

Valencia, Spain and 15 other locations

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (GEM-TECTAL)

after Intensification therapy) and safety of Tec-Dara (Teclistamab+Daratumumab) and Tal-Dara (Talquetamab+Daratumumab) in de novo high-risk multiple...

Active, not recruiting
High-Risk de Novo Multiple Myeloma
Drug: Daratumumab
Drug: Bortezomib

Phase 2

PETHEMA Foundation

Valencia, Spain and 9 other locations

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Active, not recruiting
Multiple Myeloma
Drug: Fludarabine
Drug: Lenalidomide

Phase 3

Stichting European Myeloma Network

Valencia, Spain and 107 other locations

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)

of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, i...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Cyclophosphamide

Phase 3

Gilead Sciences
Gilead Sciences

Valencia, Spain and 121 other locations

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding o ...

Active, not recruiting
Multiple Myeloma
Drug: Elranatamab (PF-06863135)

Phase 2

Pfizer
Pfizer

Valencia, Spain and 86 other locations

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Elranatamab

Phase 3

Pfizer
Pfizer

Valencia, Spain and 218 other locations

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma...

Active, not recruiting
Multiple Myeloma
Drug: CC-220
Drug: Bortezomib (BTZ)

Phase 1, Phase 2

Celgene
Celgene

Valencia, Spain and 161 other locations

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)

(Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Bortezomib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Valencia, Spain and 118 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems